圣湘生物科技股份有限公司 2025 年第四次临时股东会会议资料 二〇二五年十一月 | | | 圣湘生物科技股份有限公司（688289）2025 年第四次临时股东会会议资料 2025 年第四次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》以及 《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"）《圣湘生物科 技股份有限公司股东会议事规则》等相关规定，圣湘生物科技股份有限公司（以 下简称"公司"或"圣湘生物"）特制定 2025 年第四次临时股东会会议须知： 一、为保证股东会的严肃性和正常秩序，切实维护股东的合法权益，出席会 议的股东及股东代理人须在会议召开前 15 分钟到会议现场办理签到手续，并请 按规定出示身份证明文件或企业营业执照/注册证书复印件（加盖公章）、授权 委托书等，经验证后领取会议资料，方可出席会议。会议开始后，会议登记应当 终止，由会议主持人宣布现场出席会议的股东和代理人人数及所持有的表决权数 量。 二、会议 ...

Core Insights - Shengxiang Bio (688289.SH) has recently obtained three product certifications and registrations, including two Class III medical device registrations and one EU CE IVDR certification [1][2] - The newly launched products include a Norovirus nucleic acid detection kit and a combined detection kit for A group rotavirus, Norovirus, and F group enteric adenovirus, which will enhance rapid identification and precise diagnosis of diarrheal pathogens [1] - The EB virus nucleic acid detection kit has received EU CE IVDR certification, expanding the company's herpes virus testing product line and demonstrating compliance with international quality and technical standards [2] Product Certifications - The products certified include: - Norovirus nucleic acid detection kit (PCR-fluorescent probe method), registration number: 国械注准20253402188 - A group rotavirus/Norovirus/F group enteric adenovirus nucleic acid detection kit (PCR-fluorescent probe method), registration number: 国械注准20253402226 - EB virus nucleic acid detection kit (fluorescent PCR method), registration number: No.V120745520012Rev.00 [1] Market Impact - The introduction of these products is expected to significantly improve clinical capabilities in diagnosing diarrheal pathogens, particularly benefiting vulnerable populations such as children and the elderly [1] - The EB virus is commonly associated with various diseases, including infectious mononucleosis and several types of cancer, highlighting the importance of the newly certified detection kit in public health [2] - The company aims to accelerate the global rollout of innovative products, contributing to public health and precision medicine [2]

Core Viewpoint - Shengxiang Biotechnology (688289.SH) has recently obtained three product certifications and registrations, enhancing its diagnostic capabilities for viral pathogens associated with gastrointestinal diseases [1] Group 1: Product Certifications - The company received two Class III medical device registrations and one EU CEIVDR certification for its products [1] - The newly launched products include a Norovirus single test and a triple test for Group A Rotavirus/Norovirus/Group F Enteric Adenovirus, aimed at improving rapid identification and precise diagnosis of diarrhea pathogens [1] Group 2: Market Impact - The products are particularly beneficial for vulnerable populations such as children and the elderly, providing a robust defense for intestinal health in these groups [1] - The EB virus detection reagent has also received EU CEIVDR certification, expanding the company's herpes virus testing product line [1] Group 3: Strategic Importance - The certifications signify that the company's products meet international quality, technical performance, and management system standards, marking a significant achievement in its molecular diagnostics and internationalization strategies [1]

Core Viewpoint - Shengxiang Bio (688289.SH) has recently obtained three product certifications and registrations, enhancing its diagnostic capabilities for viral pathogens associated with gastrointestinal diseases [1] Group 1: Product Certifications - The company received two Class III medical device registrations and one EU CEIVDR certification [1] - The newly launched products include a Norovirus single test and a triple test for Group A Rotavirus/Norovirus/Group F Enterovirus, aimed at improving rapid identification and precise diagnosis of diarrhea pathogens [1] Group 2: Market Impact - The new products are expected to significantly bolster the clinical diagnosis capabilities for key demographics, particularly children and the elderly, thereby strengthening intestinal health defenses in these vulnerable groups [1] - The EB virus detection reagent has also received EU CEIVDR certification, expanding the company's herpes virus testing product line [1] Group 3: Strategic Importance - The certifications indicate that the company's products meet stringent international standards in quality, technical performance, and management systems [1] - This achievement is a significant milestone in the company's molecular diagnostics strategy and internationalization efforts [1]

Core Viewpoint - The company plans to establish a partnership fund with a target fundraising scale of 1 billion yuan, focusing on investments in AI medical applications and innovative pharmaceuticals and medical devices [1] Group 1: Fund Details - The company will contribute 370 million yuan, representing a 37% stake in the fund [1] - The fund will not be included in the company's consolidated financial statements, limiting the risk exposure to the amount contributed [1] - The proposal will be reviewed and voted on at the temporary shareholders' meeting scheduled for November 17, 2025 [1]

圣湘生物公告，公司近日获得三项产品认证及注册，其中两项为国家三类医疗器械注册证，一项为欧盟 CE IVDR 认证。 ...

Core Insights - A new company, Changsha Shengwei Tongjia Biotechnology Co., Ltd., has been established, focusing on the production and sales of medical devices and human genetic diagnosis and treatment technology development [1] Company Overview - The legal representative of the newly established company is Dai Liqun [1] - The company is wholly owned by Shengxiang Biology (688289) through indirect holdings [1] Business Scope - The business scope includes the production of Class II and Class III medical devices, as well as the sales of Class II medical devices [1] - The company is also involved in the development of human genetic diagnosis and treatment technologies [1]

Group 1 - Zhejiang Social Security Science and Technology Innovation Fund officially launched with an initial scale of 50 billion yuan, aimed at supporting national innovation-driven development strategies [7] - Hunan's Xiangwang Mother Fund completed registration with a total scale of 5 billion yuan, focusing on key industries such as smart terminals and advanced energy storage [8] - Four industrial funds were established in Hainan with an initial scale exceeding 2 billion yuan, targeting emerging industries like aerospace and intelligent manufacturing [9] Group 2 - The first venture capital mother fund in Hechi City was registered with a total scale of 1 billion yuan, focusing on strategic emerging industries and regional特色产业 [10] - The Anhui Artificial Intelligence Theme Mother Fund's first acquisition sub-fund was established with a scale of 1 billion yuan, aiming to support the AI industry cluster in Anhui [11] - The Changsha National Control-led industrial investment fund was established with a scale of 1 billion yuan, focusing on new strategic industries [12] Group 3 - The first concept verification fund in Xiong'an New Area was established with an initial scale of 20 million yuan, supporting key industries like aerospace information and biotechnology [12] - Wuhan's first batch of concept verification funds was launched, including 10 sub-funds with a total annual funding pool of 112.5 million yuan, focusing on cutting-edge fields [13] - Jiangsu Yangzhou's special mother fund for digital electronic information integration was established with a scale of 2.3 billion yuan, targeting integrated circuits and AI [14] Group 4 - China Information Technology Group established an industrial investment fund in Wuhan with a contribution of 5 billion yuan, focusing on strategic emerging industries [15] - Huatai Zhanxin (Changzhou) New Energy Fund completed registration with a total scale of 1 billion yuan, targeting new energy sectors [16] - Shanghai Xinjuce Source Fund completed its first batch of signings with a scale of 450 million yuan, focusing on high-end manufacturing and new materials [17] Group 5 - Zhuhai's Pearl Light New Intelligence Fund completed registration, focusing on high-end intelligent manufacturing [18] - A new biomedical manufacturing fund was launched in Shanghai, aiming to integrate industry resources and support key technology breakthroughs [19] - Chengdu's high-level talent innovation and entrepreneurship investment fund was established with a scale of 1 billion yuan, providing full lifecycle capital support for high-level talent projects [20]

Group 1 - The core transaction on October 31 involved a block trade of 700,000 shares of Shengxiang Bio, with a transaction value of 12.08 million yuan and a transaction price of 17.26 yuan, representing a discount of 21.72% compared to the closing price of 22.05 yuan on the same day [2][3] - The buyer and seller of the block trade were both from CITIC Securities Co., Ltd. Sichuan Branch [2][3] - On the same day, Shengxiang Bio's stock price increased by 2.23%, with a trading volume of 2.02 billion yuan and a net inflow of main funds amounting to 545,200 yuan [2][3] Group 2 - The latest margin financing balance for Shengxiang Bio is 420 million yuan, which has decreased by 13.375 million yuan over the past five days, reflecting a decline of 3.08% [3] - Shengxiang Bio was established on April 23, 2008, with a registered capital of 5,793.88006 million yuan [3]

Core Viewpoint - The company, Shengxiang Biology, announced on October 31 that several of its nucleic acid testing kits for respiratory viruses have received medical device registration certificates from the National Medical Products Administration of China, indicating regulatory approval for these products [1] Product Approval - The approved products include nucleic acid testing kits for respiratory syncytial virus, influenza A and B viruses, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR methods [1] - The approval of these products is expected to enhance the company's market presence and product offerings in the diagnostic sector [1] Future Performance Uncertainty - The future performance of these products will be influenced by multiple factors, including market expansion efforts, brand influence, and actual market demand [1] - The company has indicated that the sales and profit contributions from these products remain uncertain, making it difficult to predict their specific impact on future performance [1]